Hormonal Treatment for Endometriosis, Adenomyosis, and Fibromatosis

Claudia Silvestri, Alice Baronti, Giovanni Ferraro, Francesca Papini, Cela, Andrea Giannini, Tommaso Simoncini, Stefano Luisi, Stefano Vincenzo Luisi
In: Reproductive Medicine for Clinicians · 2026 · pp. 229–236 · doi:10.1007/978-3-032-07322-8_13 · W7127625766
book-chapter OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-06 ⓘ

Hormonal treatments like progestins and GnRH analogues manage endometriosis, adenomyosis, and fibromatosis symptoms, with new drugs targeting these conditions under development.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 ⓘ

This chapter reviews medical/hormonal treatments for benign uterine conditions including endometriosis, adenomyosis, and fibromatosis, describing women at different ages and symptoms and focusing on off-label hormonal approaches used to control pain, abnormal uterine bleeding, and infertility. It summarizes a mechanistic rationale linking therapy to sex-steroid hormone aberrations, impaired apoptosis, and inflammation, and notes that progestins (e.g., dienogest, danazol, norethindrone acetate) are described as antiproliferative/anti-inflammatory for pain control, while a levonorgestrel-releasing intrauterine device is described as highly effective for abnormal uterine bleeding and reducing uterine volume long term. A key limitation explicitly stated is that the manuscript does not include primary research with human participants. This paper is centrally about endometriosis and adenomyosis — it provides a mechanistic and therapeutic overview of hormonal treatments used for their pain and bleeding manifestations.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK